Here’s what we’re watching in chemistry business news this week Read more
Chemical & Engineering News - Nov 25
Moderna Inc. continues to push its cost-savings work as Covid-19 vaccination rates decline. The Cambridge drugmaker announced third-quarter revenue of $1 billion on Thursday — a 45% decrease from the same time in 2024. Moderna (Nasdaq: MRNA) said the drop off was mainly due to lower Covid-19 vacc... Read more
Necn - Nov 06
Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.The ... Read more
Benzinga - Oct 23
Moderna's experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial Read more
Stat - Oct 23
With other Readout newsletter updates on the biggest news stories in biotech. Read more
Stat - Oct 23
Patients with an aggressive form of breast cancer will likely have new treatment options after AstraZeneca and Gilead presented successful trial results Read more
Stat - Oct 20
Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialogue with the FDA—but acknowledged recent setbacks. Read more
Wired - Sep 09
